Welcome to our dedicated page for Staar Surg SEC filings (Ticker: STAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The STAAR Surgical Company (NASDAQ: STAA) SEC filings page on Stock Titan brings together the company’s official disclosures from the U.S. Securities and Exchange Commission. STAAR is a medical device manufacturer focused on ophthalmic surgery, and its filings provide detailed information on its implantable intraocular lens business, corporate actions, and governance.
Investors can review Current Reports on Form 8-K in which STAAR reports material events, such as the August 2025 Agreement and Plan of Merger with Alcon, subsequent amendments, the go-shop process, adjournments of special meetings of stockholders, and later communications about the failure to obtain shareholder approval and the intended termination of the merger agreement. Other 8-K filings describe litigation related to the merger proxy statement, preliminary and final financial results, and leadership changes, including the appointment of a Chief Financial Officer and the creation of a Capital Stewardship Committee of the Board.
Filings also confirm that STAAR’s common stock is listed on Nasdaq under the symbol STAA and document how the proposed merger, if completed, would have affected listing status and registration. By reading these documents, users can trace the evolution of STAAR’s strategic transaction with Alcon, the role of major shareholders in the process, and the company’s decision to remain a standalone, publicly traded entity after the merger was not approved.
On Stock Titan, STAAR’s SEC filings are updated as new documents are released on EDGAR. AI-powered tools summarize lengthy filings such as 8-Ks and related exhibits, helping users quickly identify key terms, conditions, and outcomes without reading every page. This makes it easier to track transaction terms, board and management changes, and other disclosures that shape the outlook for STAA within the ophthalmic medical device industry.
Broadwood group reports a 27.4% stake in STAAR Surgical (STAA) and is actively opposing the proposed merger with Alcon. The Reporting Persons—Broadwood Partners, Broadwood Capital and individuals including Neal C. Bradsher—may be deemed to beneficially own 13,519,491 shares out of 49,354,123 outstanding (approximately 27.4%). On September 15, 2025 they filed a preliminary proxy statement and a GREEN Proxy Card to solicit proxies to oppose approval of the Merger Agreement and a related non-binding compensation proposal at a special meeting scheduled for October 23, 2025. The Reporting Persons executed a Joint Filing and Solicitation Agreement on September 17, 2025 to coordinate filings and proxy solicitation; Broadwood Partners will bear pre-approved expenses. The filing discloses Mr. LeBuhn purchased 21,286 shares for approximately $135,888.02 from personal funds and that no Reporting Person transacted in the past 60 days.
STAAR Surgical Company (STAA) has entered into a merger agreement with Alcon under which STAAR stockholders will receive $28.00 per share in cash. The per-share price represented an approximately 51% premium to STAAR's closing price on August 4, 2025. Following the closing, STAAR common stock will no longer be listed and the company will cease to be publicly traded.
The board received a written fairness opinion from Citi dated August 4, 2025, and Citi used analyses that produced an implied per-share reference range of $17.70 to $37.50, adding STAAR net cash of $185 million and tax benefit present values in its valuation. The proxy discloses termination-fee mechanics, a go-shop/window period for superior proposals, employee award treatments (cash for in-the-money options; conversion or cancellation rules for RSUs/PSUs), and a Special Meeting to vote virtually on October 23, 2025. The proxy also includes multi-year financial projections showing revenue and adjusted EBITDA trajectories presented by STAAR to advisors.
Broadwood Partners, Broadwood Capital and Neal C. Bradsher disclose a combined stake in STAAR SURGICAL CO equal to 27.3% of the outstanding common stock. The filing states Broadwood Partners beneficially owns 13,519,491 shares and Mr. Bradsher beneficially owns 13,545,391 shares based on 49,553,035 shares outstanding. The Reporting Persons say they intend to vote against the definitive merger agreement under which Alcon would acquire STAAR and have issued a related press release. They also state they are exploring strategic alternatives, including contacting potential strategic and financial partners, and reserve the right to change their holdings or take other actions depending on market and deal developments.
STAAR Surgical Company (NASDAQ: STAA) has entered a merger agreement under which Alcon will acquire all outstanding STAAR shares for a Merger Consideration of $28.00 per share, representing an approximately 51% premium to STAAR's closing price on August 4, 2025. Upon closing STAAR will cease to be publicly listed and will be delisted. The parties intend to file required HSR notifications on or before September 2, 2025. Awards treatment: in‑the‑money options/payments will be cashed out; many RSU awards will be converted into Alcon RSUs using an RSU Exchange Ratio tied to Alcon's 5‑day VWAP before the Effective Time. Material termination provisions include potential STAAR termination fees (up to $43,425,000, reduced in certain circumstances to $14,475,000), an Alcon termination fee of $72,375,000, and specified regulatory closing conditions. STAAR disclosed management projections (2025E revenue ~$260M rising to ~$495M by 2030E) and noted non‑GAAP measures and tax gross‑up arrangements capped at an aggregate $15 million.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 2,812,000 shares of STAAR SURGICAL CO common stock, representing 5.67% of the class. The filing states that Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and that Armistice exercises shared voting and dispositive power over those securities. Neither reporting person holds sole voting or dispositive power. The percentage is calculated using 49,553,035 shares outstanding as of July 30, 2025. The filing includes a certification that the shares were acquired in the ordinary course of business and not to influence control of the issuer.
Jiang Wei, a director of Staar Surgical Co (STAA), had 20,967 restricted stock units (RSUs) vest on August 12, 2025. These RSUs were part of a grant made May 12, 2025 and each RSU converts into one share upon vesting. The award vests in three equal tranches of 20,967 shares on August 12, 2025, November 12, 2025 and January 12, 2026, for a total grant of 62,901 RSUs. The Form 4 shows post-transaction beneficial ownership figures and notes the RSUs relate to a consulting agreement under which Mr. Jiang serves as special strategic advisor for the companys Asia Pacific business through the end of fiscal 2025.
Broadwood Partners, L.P., Broadwood Capital, Inc. and Neal C. Bradsher (collectively the “Reporting Persons”) filed Amendment No. 35 to Schedule 13D on STAAR Surgical Company (NASDAQ: STAA). The group now reports beneficial ownership of 13,545,391 common shares (13,519,491 held jointly plus 25,900 held solely by Bradsher), representing 27.3 % of the 49,553,035 shares outstanding. Voting and dispositive power is shared over virtually all shares, underscoring the bloc’s ability to influence corporate actions.
On 5 Aug 2025 STAAR announced a definitive agreement to be acquired by Alcon. The Reporting Persons have not decided how they will vote on the transaction and are demanding books & records under Delaware §220 to evaluate the sale process. They are also exploring strategic alternatives, including contacting other potential bidders, and reserve the right to alter their holdings or take additional actions. No share transactions were executed in the past 60 days, and no borrowings were used to finance the stake.
Staar Surgical Co. (STAA) filed a Form 144 indicating a proposed sale of 1,750 common shares through broker Merrill Lynch, 520 Newport Center Dr., Newport Beach, CA. The shares represent a negligible fraction (≈0.004%) of the 49,526,129 shares outstanding. The filer values the block at $47,025.13 and plans to execute the sale on or about 08/05/2025 on the Nasdaq.
The securities were originally acquired 03/14/2024 via an open-market purchase and paid for in cash on 03/18/2024. No sales by the same beneficial owner occurred during the previous three months, and the filer attests to possessing no undisclosed material adverse information about the company.
Given the small size relative to total float and lack of additional context (e.g., identity or role of the seller), the filing signals routine liquidity management rather than a materially significant insider move.
Form 144 Filing Summary for STAAR Surgical Co (STAA)
The filer reports a proposed sale of 13,491 common shares with an aggregate market value of $362,523.41, with an approximate sale date of 08/05/2025 on NASDAQ. Total shares outstanding are listed as 49,526,129. Broker: Merrill Lynch, 520 Newport Center Drive, Floor 20, Newport Beach, CA.
Acquisition details provided: 2,000 shares acquired via open market purchase on 08/07/2023 (cash paid 08/09/2023); 3,417 shares from RSU vesting on 06/15/2024; 8,074 shares from RSU vesting on 06/18/2025. The filer reports Nothing to Report for securities sold during the past three months.
FAQ
What is the current stock price of Staar Surg (STAA)?
What is the market cap of Staar Surg (STAA)?
